Vanguard Global Advisers
VTGN icon

Vanguard Global Advisers’s VistaGen Therapeutics VTGN Stock Holding History

Vanguard Global Advisers’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.44K Hold
10,809
– – ﹤0.01% 3595
2026
Q1 		$6.18K Buy
+10,809
New +$6.57K ﹤0.01% 3539

Other funds holding VTGN

CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
LM
Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Global Advisers's VTGN Position: Q2 2026 in Review

Vanguard Global Advisers held its VistaGen Therapeutics (VTGN) position steady in Q2 2026 at 10,809 shares worth $2.44K. The position accounts for ﹤0.01% of the portfolio, ranked #3595.

Vanguard Global Advisers first reported a position in VTGN in Q1 2026 and has held it in 2 quarters since. The position peaked at $6.18K in Q1 2026. 46 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • Vanguard Global Advisers held 10,809 shares of VistaGen Therapeutics worth $2.44K as of Q2 2026.
  • Vanguard Global Advisers left its VistaGen Therapeutics share count unchanged in Q2 2026.
  • VistaGen Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3595 holding.
  • Vanguard Global Advisers first reported a position in VistaGen Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's VistaGen Therapeutics position peaked at $6.18K in Q1 2026.
  • 46 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.